Carboplatin News and Research RSS Feed - Carboplatin News and Research

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]
Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology. [More]
STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. [More]
Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. [More]
Uninsured cancer patients may face higher charges for chemotherapy drugs

Uninsured cancer patients may face higher charges for chemotherapy drugs

Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill. [More]
Combination treatment improves outcomes in women with ovarian cancer

Combination treatment improves outcomes in women with ovarian cancer

Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult. [More]
SRS fails to improve survival for NSCLC brain metastases patients

SRS fails to improve survival for NSCLC brain metastases patients

Phase III trial findings suggest that carrying out stereotactic radiosurgery before chemotherapy does not improve overall survival for non-small-cell lung cancer patients with asymptomatic brain metastases compared with chemotherapy alone. [More]
Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Combination therapy with amrubicin and carboplatin is moderately effective in patients with advanced thymic carcinoma, a Japanese study finds, but invasive thymoma patients do not benefit from this regimen. [More]
Two-drug combination before surgery benefits women with triple-negative breast cancer

Two-drug combination before surgery benefits women with triple-negative breast cancer

A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer. [More]
Carboplatin and paclitaxel show promise for advanced thymic carcinoma

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy. [More]
Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC. [More]

Experimental drug may help fight cervical cancer

University of Leicester academic leads study into effects of cediranib drug in chemotherapy treatment of cervical cancer. [More]
Six platinum cycles no better than four for advanced NSCLC

Six platinum cycles no better than four for advanced NSCLC

Six cycles of adjuvant platinum-based chemotherapy is no better than three or four cycles for patients with advanced non-small-cell lung cancer, meta-analysis results suggests. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid. [More]
Study could lead to improvements in outcomes for women with triple-negative breast cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women. [More]
Tumor genetic analysis reveals new approach of classifying cancers

Tumor genetic analysis reveals new approach of classifying cancers

Researchers with The Cancer Genome Atlas (TCGA) Research Network have completed the largest, most diverse tumor genetic analysis ever conducted, revealing a new approach to classifying cancers. [More]
Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014. [More]
Advertisement
Advertisement